References
- Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016; 387:1094-108. doi: 10.1016/S0140-6736(15)00130-0
- Repše-Fokter A. Endometrial cancer in young woman. Acta Medico– Biotechnica 2020; 13: 60-4.
- Zadnik V, Zagar T, Lokar K, Tomsic S, Konjevic AD, Zakotnik B. Trends in population-based cancer survival in Slovenia. Radiol Oncol 2021; 55: 42-9. doi: 10.2478/raon-2021-0003
- Concin N, Matias-guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12-39. doi: 10.1136/ijgc-2020-002230
- Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer 2019; 19: 510-21. doi: 10.1038/s41568-019-0177-x
- Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73. doi: 10.1038/nature12113
- Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119: 1067-74. doi: 10.1038/s41416-018-0310-8
- McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. Cancer 2021; 26: 5400-10. doi: 10.1002/cncr.33516
- Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology 2020; 76: 52-63. doi: 10.1111/his.14015
- Abdulfatah E, Wakeling E, Sakr S, Al-Obaidy K, Bandyopadhyay S, Morris R, et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management. Gynecol Oncol 2019; 154: 467-74. doi: 10.1016/j.ygyno.2019.06.012
- Malentacchi F, Turrini I, Sorbi F, Projetto E, Castiglione F, Vergoni F, et al. Identification of a gene panel for endometrioid endometrial cancer: a possible prognostic value? Reprod Sci 2020; 27: 592-8. doi: 10.1007/s43032-019-00059-8
- McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538-49. doi: 10.1002/path.5034
- Raffone A, Travaglino A, Cerbone M, Guida M, Insabato L, Zannoni GF, et al. Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res 2020; 26: 1417-27. doi: 10.1007/s12253-020-00811-5
- Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas. Int J Gynecol Pathol 2019; 38: S123-S131. doi: 10.1097/PGP.0000000000000488
- Ayhan A, Şahin H, Sari ME, Yalçin I, Haberal A, Meydanli MM. Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer. Int J Gynecol Cancer 2019; 29: 505-12. doi: 10.1136/ijgc-2018-000069
- Oberndorfer F, Moling S, Hagelkruys LA, Grimm C, Polterauer S, Sturdza A, et al. Risk reclassification of patients with endometrial cancer based on tumor molecular profiling: First real world data. J Pers Med 2021; 11: 1-11. doi: 10.3390/jpm11010048
- Colombo N, Creutzberg C, Amant F, Cibula D, Mirza MR, Marnitz S, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer. Int J Gynecol Cancer 2016; 26: 2-30. doi: 10.1097/igc.0000000000000609
- Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol 2013; 26: 1594-604. doi: 10.1038/modpathol.2013.102
- Sobočan M, Ogrizek AM, Ledinek T, Takač I, Knez J. Importance of preoperative ultrasound examination and pathological tumour evaluation in the management of women with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2021; 257: 121-126. doi: 10.1016/j.ejogrb.2020.12.029
- Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Uterine serous carcinoma. Gynecol Oncol 2021; 162: 226-34. doi: 10.1016/j.ygyno.2021.04.029
- Van Den Heerik ASVM, Horeweg N, De Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer 2021; 31: 594-604. doi: 10.1136/ijgc-2020-001822
- Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113: 299-310. doi: 10.1038/bjc.2015.190
- Kommoss FKF, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, et al. L1cam further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 2018; 119: 480-6. doi: 10.1038/s41416-018-0187-6
- Weinberger V, Bednarikova M, Hausnerova J, Ovesna P, Vinklerova P, Minar L, et al. A novel approach to preoperative risk stratification in endometrial cancer: The added value of immunohistochemical markers. Front Oncol 2019; 9: 1-13. doi: 10.3389/fonc.2019.00265
- Imboden S, Tapia C, Scheiwiller N, Kocbek V, Altermatt HJ, Janzen J et al. Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence. Acta Obstet Gynecol Scand 2020; 99: 196-203. doi: 10.1111/aogs.13740
- Kolehmainen A, Pasanen A, Tuomi T, Koivisto-Korander R, Butzow R, Loukovaara M. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. PLoS One 2020; 15:1-12. doi: 10.1371/journal.pone.0242733
- León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 2020; 250: 312-22. doi: 10.1002/path.5373
- Leon-Castillo A, De Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020; 38: 3388-97. doi: 10.1200/JCO.20.00549